triamcinolone acetonide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids not used as glucocorticosteroids 2726 76-25-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nasacort
  • triamcinolone acetonide
  • aristicort
  • allernaze
An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.
  • Molecular weight: 434.50
  • Formula: C24H31FO6
  • CLOGP: 2.21
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.06
  • ALOGS: -4.01
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.11 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.26 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 23 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1960 FDA APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site atrophy 264.56 11.04 61 25317 482 46660202
Adrenal insufficiency 187.37 11.04 106 25272 13018 46647666
Soft tissue disorder 172.21 11.04 70 25308 4116 46656568
Skin atrophy 121.10 11.04 55 25323 4245 46656439
Non-infectious endophthalmitis 115.26 11.04 26 25352 184 46660500
Endophthalmitis 115.22 11.04 49 25329 3229 46657455
Pneumonia viral 101.33 11.04 56 25322 6568 46654116
Body height below normal 94.04 11.04 36 25342 1803 46658881
Synovitis 92.03 11.04 138 25240 60937 46599747
Arthritis 89.57 11.04 155 25223 77161 46583523
Human antichimeric antibody positive 88.51 11.04 32 25346 1364 46659320
Joint destruction 82.53 11.04 38 25340 3026 46657658
Fibromyalgia 80.18 11.04 99 25279 36364 46624320
Liver function test abnormal 80.17 11.04 112 25266 46375 46614309
Blood cholesterol increased 75.96 11.04 101 25277 39912 46620772
Juvenile idiopathic arthritis 74.59 11.04 39 25339 4093 46656591
Wheelchair user 72.84 11.04 38 25340 3970 46656714
Intraocular pressure increased 71.48 11.04 43 25335 5914 46654770
Obesity 70.79 11.04 60 25318 14146 46646538
Toxicity to various agents 67.73 11.04 16 25362 211750 46448934
Polyarthritis 62.82 11.04 41 25337 6501 46654183
Hypothalamic pituitary adrenal axis suppression 61.80 11.04 15 25363 151 46660533
Cushing's syndrome 57.48 11.04 20 25358 761 46659923
Bone density decreased 56.58 11.04 45 25333 9707 46650977
Antibody test positive 55.67 11.04 26 25352 2139 46658545
Bursitis infective 49.49 11.04 20 25358 1157 46659527
Retinal artery occlusion 49.41 11.04 21 25357 1381 46659303
Rhegmatogenous retinal detachment 48.87 11.04 11 25367 77 46660607
Urticarial vasculitis 46.86 11.04 15 25363 439 46660245
Psoriasis 46.76 11.04 120 25258 78484 46582200
Necrotising scleritis 46.28 11.04 12 25366 161 46660523
Ocular hypertension 45.89 11.04 17 25361 777 46659907
Visual acuity reduced 45.35 11.04 58 25320 22055 46638629
Herpes zoster 44.99 11.04 108 25270 67764 46592920
Death 44.66 11.04 71 25307 335477 46325207
Secondary adrenocortical insufficiency 44.28 11.04 17 25361 858 46659826
Adrenal suppression 42.90 11.04 17 25361 934 46659750
Retinal pigment epithelial tear 42.25 11.04 12 25366 231 46660453
Acute kidney injury 40.62 11.04 41 25337 235814 46424870
Maculopathy 40.35 11.04 19 25359 1592 46659092
Injection site discolouration 40.33 11.04 32 25346 6878 46653806
Eye infection toxoplasmal 39.83 11.04 12 25366 286 46660398
Postmenopausal haemorrhage 39.22 11.04 20 25358 1993 46658691
Drug specific antibody 35.11 11.04 16 25362 1244 46659440
Lipoatrophy 33.92 11.04 11 25367 336 46660348
Soft tissue swelling 33.48 11.04 14 25364 884 46659800
Macular degeneration 32.99 11.04 29 25349 7176 46653508
Intentional product use issue 32.86 11.04 82 25296 52698 46607986
Chorioretinopathy 32.57 11.04 13 25365 728 46659956
Atrophy 31.92 11.04 16 25362 1537 46659147
Gastroenteritis viral 31.73 11.04 44 25334 18075 46642609
Tractional retinal detachment 31.22 11.04 7 25371 48 46660636
Immunodeficiency 31.10 11.04 37 25341 13069 46647615
Leukopenia 30.48 11.04 94 25284 68249 46592435
Therapeutic product effect incomplete 29.89 11.04 102 25276 78051 46582633
Human anti-human antibody test 29.76 11.04 10 25368 342 46660342
Tenderness 28.09 11.04 40 25338 16841 46643843
Product contamination 25.49 11.04 10 25368 535 46660149
Eye inflammation 25.19 11.04 19 25359 3790 46656894
Hypopyon 24.83 11.04 11 25367 800 46659884
Dermatitis contact 24.52 11.04 26 25352 8097 46652587
Cushingoid 24.34 11.04 23 25355 6243 46654441
Drug abuse 24.16 11.04 3 25375 63405 46597279
Orbital infection 23.81 11.04 5 25373 24 46660660
Spinal cord infarction 23.41 11.04 8 25370 288 46660396
Renal impairment 23.01 11.04 6 25372 74366 46586318
Scleral thinning 22.88 11.04 5 25373 30 46660654
Red blood cell sedimentation rate increased 22.79 11.04 43 25335 22846 46637838
Skin discolouration 22.72 11.04 53 25325 32627 46628057
Therapy non-responder 22.59 11.04 61 25317 41091 46619593
Polypoidal choroidal vasculopathy 22.10 11.04 6 25372 97 46660587
Blindness 21.79 11.04 36 25342 17233 46643451
Muscle atrophy 21.42 11.04 21 25357 5963 46654721
Conjunctival ulcer 21.41 11.04 5 25373 42 46660642
Bradycardia 21.18 11.04 5 25373 66293 46594391
Keratitis fungal 20.95 11.04 6 25372 119 46660565
Overdose 20.86 11.04 15 25363 101964 46558720
Infection 20.78 11.04 134 25244 133458 46527226
Intentional overdose 20.55 11.04 5 25373 64939 46595745
Vitreous opacities 20.43 11.04 7 25371 254 46660430
Retinal scar 19.72 11.04 6 25372 148 46660536
Peripheral vascular disorder 19.60 11.04 20 25358 5957 46654727
Peripheral swelling 19.58 11.04 150 25228 157921 46502763
Thrombocytopenia 19.57 11.04 24 25354 126557 46534127
Exposure via breast milk 19.50 11.04 11 25367 1341 46659343
Epicondylitis 19.42 11.04 12 25366 1730 46658954
Acute febrile neutrophilic dermatosis 19.12 11.04 14 25364 2671 46658013
Injection site fibrosis 19.09 11.04 4 25374 19 46660665
Systemic lupus erythematosus 18.79 11.04 6 25372 65174 46595510
Pseudoendophthalmitis 18.45 11.04 4 25374 23 46660661
Detachment of retinal pigment epithelium 18.33 11.04 7 25371 348 46660336
Vitreous disorder 18.30 11.04 5 25373 83 46660601
Septic shock 18.27 11.04 71 25307 57822 46602862
Skin hypopigmentation 18.24 11.04 7 25371 353 46660331
Bone density increased 18.16 11.04 7 25371 357 46660327
Oral pain 18.10 11.04 41 25337 24756 46635928
Conjunctival haemorrhage 17.81 11.04 14 25364 2967 46657717
Intra-abdominal haematoma 17.59 11.04 11 25367 1620 46659064
Coma 17.50 11.04 5 25373 58344 46602340
Purpura senile 17.49 11.04 8 25370 627 46660057
Infective scleritis 17.48 11.04 3 25375 3 46660681
Eye infection fungal 17.28 11.04 5 25373 103 46660581
Retinal haemorrhage 17.23 11.04 17 25361 4866 46655818
Hypocalcaemia 17.07 11.04 42 25336 26743 46633941
Injection site abscess 16.82 11.04 9 25369 990 46659694
Injection site necrosis 16.77 11.04 10 25368 1352 46659332
Product use issue 16.64 11.04 98 25280 94546 46566138
Joint effusion 16.49 11.04 26 25352 11969 46648715
Pyloric abscess 16.26 11.04 3 25375 6 46660678
Staphylococcal infection 15.75 11.04 49 25329 35722 46624962
Rhinitis allergic 15.57 11.04 19 25359 6889 46653795
Drug specific antibody present 15.49 11.04 13 25365 3023 46657661
Rapidly progressive osteoarthritis 15.40 11.04 3 25375 9 46660675
Bronchiectasis 15.39 11.04 22 25356 9294 46651390
Pemphigus 15.31 11.04 3 25375 45271 46615413
Parakeratosis 15.08 11.04 5 25373 164 46660520
Arthritis bacterial 14.95 11.04 17 25361 5719 46654965
Chorioretinal folds 14.94 11.04 3 25375 11 46660673
Neutropenia 14.90 11.04 35 25343 143169 46517515
Dermatophytosis 14.82 11.04 5 25373 173 46660511
Retinal detachment 14.82 11.04 16 25362 5084 46655600
Infusion related reaction 14.80 11.04 20 25358 101188 46559496
Cardio-respiratory arrest 14.80 11.04 7 25371 59862 46600822
Impaired quality of life 14.74 11.04 13 25365 3229 46657455
Tarsal tunnel syndrome 14.21 11.04 7 25371 648 46660036
Short stature 14.20 11.04 5 25373 197 46660487
Retinal artery embolism 14.13 11.04 4 25374 76 46660608
Loss of personal independence in daily activities 14.06 11.04 65 25313 57118 46603566
General physical health deterioration 13.98 11.04 26 25352 115743 46544941
Diabetic ulcer 13.76 11.04 5 25373 216 46660468
Cardiac failure 13.62 11.04 14 25364 79934 46580750
Bursitis 13.60 11.04 32 25346 19810 46640874
Iridoschisis 13.59 11.04 3 25375 19 46660665
Upper respiratory tract infection bacterial 13.58 11.04 4 25374 88 46660596
Quality of life decreased 13.36 11.04 16 25362 5686 46654998
Skin depigmentation 13.28 11.04 7 25371 746 46659938
Resorption bone increased 13.17 11.04 8 25370 1119 46659565
Rotator cuff syndrome 13.10 11.04 23 25355 11560 46649124
Cardiac arrest 13.08 11.04 18 25360 90381 46570303
Injection site scar 13.05 11.04 7 25371 773 46659911
Steroid withdrawal syndrome 12.94 11.04 6 25372 485 46660199
Hyponatraemia 12.91 11.04 22 25356 101310 46559374
Seizure 12.86 11.04 30 25348 123024 46537660
Somnolence 12.77 11.04 43 25335 156478 46504206
Arthralgia 12.73 11.04 273 25105 364330 46296354
Ear discomfort 12.72 11.04 17 25361 6744 46653940
Pruritus 12.51 11.04 193 25185 242159 46418525
Retinal degeneration 12.45 11.04 6 25372 529 46660155
Necrotising retinitis 12.39 11.04 5 25373 288 46660396
Pancytopenia 12.24 11.04 17 25361 85041 46575643
Metabolic acidosis 12.24 11.04 3 25375 38777 46621907
Osteoporosis 12.16 11.04 49 25329 40559 46620125
Flushing 12.07 11.04 68 25310 64546 46596138
Hyperadrenocorticism 12.00 11.04 5 25373 313 46660371
Spinal cord ischaemia 11.96 11.04 3 25375 35 46660649
Incorrect route of product administration 11.86 11.04 27 25351 16356 46644328
C-reactive protein increased 11.84 11.04 63 25315 58527 46602157
Maternal exposure during pregnancy 11.54 11.04 24 25354 102525 46558159
Cataract subcapsular 11.44 11.04 6 25372 633 46660051
Phantom limb syndrome 11.35 11.04 4 25374 158 46660526
Gingival blister 11.32 11.04 3 25375 44 46660640
Glossodynia 11.26 11.04 5 25373 44368 46616316
Electrocardiogram QT prolonged 11.23 11.04 7 25371 51318 46609366
Joint injury 11.07 11.04 29 25349 19180 46641504
Cytomegalovirus chorioretinitis 11.05 11.04 8 25370 1499 46659185

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endophthalmitis 306.82 12.45 92 10467 3388 29938531
Visual acuity reduced 177.32 12.45 94 10465 15752 29926167
Non-infectious endophthalmitis 148.56 12.45 29 10530 152 29941767
Intraocular pressure increased 121.33 12.45 51 10508 5069 29936850
Ocular hypertension 111.55 12.45 30 10529 738 29941181
Maculopathy 84.63 12.45 25 10534 871 29941048
Uveitis 83.24 12.45 40 10519 5437 29936482
Chorioretinopathy 80.61 12.45 27 10532 1425 29940494
Choroiditis 77.56 12.45 23 10536 812 29941107
Eye infection toxoplasmal 65.41 12.45 15 10544 186 29941733
Macular oedema 63.94 12.45 27 10532 2711 29939208
Hypothalamic pituitary adrenal axis suppression 59.15 12.45 14 10545 201 29941718
Eye pain 57.07 12.45 41 10518 11748 29930171
Adrenal suppression 56.90 12.45 17 10542 616 29941303
Injection site atrophy 52.12 12.45 10 10549 47 29941872
Eye inflammation 51.51 12.45 20 10539 1617 29940302
Retinal artery occlusion 50.96 12.45 20 10539 1664 29940255
Infective scleritis 48.69 12.45 8 10551 11 29941908
Hypopyon 48.14 12.45 14 10545 461 29941458
Intentional product use issue 46.98 12.45 61 10498 36379 29905540
Glaucoma 46.87 12.45 28 10531 5880 29936039
Dermatitis contact 44.30 12.45 22 10537 3209 29938710
Macular fibrosis 41.62 12.45 12 10547 383 29941536
Diabetic retinal oedema 40.72 12.45 11 10548 275 29941644
Toxicity to various agents 40.29 12.45 7 10552 177176 29764743
Product contamination 39.76 12.45 13 10546 636 29941283
Cystoid macular oedema 39.07 12.45 13 10546 672 29941247
Retinal haemorrhage 36.39 12.45 22 10537 4721 29937198
Retinal artery embolism 35.20 12.45 7 10552 41 29941878
Necrotising retinitis 34.45 12.45 12 10547 713 29941206
Psoriasis 32.89 12.45 56 10503 42450 29899469
Product use issue 30.93 12.45 57 10502 45959 29895960
Skin hypopigmentation 30.87 12.45 9 10550 299 29941620
Symmetrical drug-related intertriginous and flexural exanthema 30.76 12.45 8 10551 172 29941747
Retinal detachment 30.14 12.45 20 10539 5040 29936879
Subretinal fluid 28.82 12.45 8 10551 222 29941697
Retinal pigment epithelial tear 27.88 12.45 8 10551 251 29941668
Uveitis-glaucoma-hyphaema syndrome 26.72 12.45 5 10554 20 29941899
Choroidal infarction 25.23 12.45 6 10553 88 29941831
Distal intestinal obstruction syndrome 25.17 12.45 8 10551 357 29941562
Visual field defect 25.14 12.45 17 10542 4419 29937500
Blindness 24.91 12.45 26 10533 12283 29929636
Adrenal insufficiency 24.66 12.45 24 10535 10439 29931480
Anaphylactic reaction 24.52 12.45 39 10520 27943 29913976
Cauda equina syndrome 24.49 12.45 8 10551 390 29941529
Vitreous opacities 24.23 12.45 7 10552 225 29941694
Expired product administered 23.81 12.45 14 10545 2855 29939064
Pseudoendophthalmitis 23.36 12.45 5 10554 44 29941875
Injection site calcification 22.80 12.45 4 10555 10 29941909
Completed suicide 22.44 12.45 4 10555 99488 29842431
Open globe injury 22.02 12.45 4 10555 13 29941906
Vitritis 20.34 12.45 8 10551 669 29941250
Spinal cord infarction 19.96 12.45 6 10553 222 29941697
Rhegmatogenous retinal detachment 19.89 12.45 4 10555 25 29941894
Anterior chamber inflammation 19.44 12.45 6 10553 243 29941676
Cataract subcapsular 19.34 12.45 6 10553 247 29941672
Retinal degeneration 19.03 12.45 6 10553 261 29941658
Central vision loss 18.92 12.45 4 10555 33 29941886
Cataract 18.53 12.45 30 10529 21805 29920114
Arthritis bacterial 18.18 12.45 14 10545 4450 29937469
Eye abscess 17.51 12.45 5 10554 154 29941765
Pain 17.30 12.45 112 10447 172529 29769390
Drug abuse 17.05 12.45 4 10555 82068 29859851
Arthritis infective 16.87 12.45 11 10548 2691 29939228
Amblyopia 16.74 12.45 4 10555 60 29941859
Cardiac arrest 16.59 12.45 6 10553 92844 29849075
Cushing's syndrome 15.80 12.45 6 10553 456 29941463
Lenticular opacities 15.73 12.45 5 10554 223 29941696
Vision blurred 15.71 12.45 41 10518 41775 29900144
Oesophageal perforation 15.67 12.45 6 10553 467 29941452
Mycobacterium kansasii infection 15.61 12.45 5 10554 229 29941690
Retinal oedema 15.08 12.45 6 10553 517 29941402
Application site pruritus 14.87 12.45 8 10551 1375 29940544
Intracranial hypotension 14.83 12.45 5 10554 269 29941650
Visual impairment 14.83 12.45 33 10526 30405 29911514
Subretinal fibrosis 14.73 12.45 4 10555 102 29941817
Incorrect route of product administration 14.66 12.45 19 10540 11296 29930623
Drug ineffective 14.42 12.45 183 10376 340204 29601715
Dermatitis 14.37 12.45 16 10543 8126 29933793
Rash 14.32 12.45 116 10443 191773 29750146
Vitrectomy 14.11 12.45 4 10555 120 29941799
Death 13.83 12.45 72 10487 357211 29584708
Cellulitis orbital 13.69 12.45 5 10554 341 29941578
Skin burning sensation 13.56 12.45 11 10548 3769 29938150
Skin exfoliation 13.47 12.45 27 10532 23145 29918774
Chondritis 13.18 12.45 4 10555 153 29941766
Dry skin 12.85 12.45 26 10533 22428 29919491
Cushingoid 12.84 12.45 9 10550 2478 29939441
Rash pruritic 12.76 12.45 26 10533 22546 29919373
Stomatitis 12.45 12.45 35 10524 37244 29904675

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:50857 anti-allergic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Cerebral edema indication 2032001
Lichen planus indication 4776004 DOID:9201
Berylliosis indication 8247009 DOID:10322
Psoriasis indication 9014002 DOID:8893
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatic heart disease indication 23685000
Atopic dermatitis indication 24079001 DOID:3310
Inflammatory bowel disease indication 24526004 DOID:0050589
Multiple sclerosis indication 24700007 DOID:2377
Severe adrenal insufficiency indication 24867002
Sarcoidosis indication 31541009 DOID:11335
Idiopathic thrombocytopenic purpura indication 32273002 DOID:8924
Psoriasis with arthropathy indication 33339001
Keloid scar indication 33659008
Crohn's disease indication 34000006
Tendinitis indication 34840004 DOID:971
Erythema multiforme indication 36715001
Contact dermatitis indication 40275004 DOID:2773
Angioedema indication 41291007 DOID:1558
Humoral hypercalcemia of malignancy indication 47709007
Articular gout indication 48440001 DOID:13189
Candidiasis of skin indication 49883006
Seborrheic dermatitis indication 50563003 DOID:8741
Edema of larynx indication 51599000
Nephrotic syndrome indication 52254009 DOID:1184
Lichen simplex chronicus indication 53891004
Systemic lupus erythematosus indication 55464009 DOID:9074
Allergic rhinitis indication 61582004
Löffler's syndrome indication 64936001 DOID:9503
Pemphigus indication 65172003 DOID:9182
Granuloma annulare indication 65508009 DOID:3777
Tenosynovitis indication 67801009 DOID:970
Alopecia areata indication 68225006 DOID:986
Rheumatoid arthritis indication 69896004 DOID:7148
Transfusion reaction due to serum protein reaction indication 72284000
Epicondylitis indication 73583000 DOID:14087
Acquired thrombocytopenia indication 74576004 DOID:11126
Sympathetic uveitis indication 75315001 DOID:12029
Thyroiditis indication 82119001 DOID:7166
Bursitis indication 84017003 DOID:2965
Autoimmune disease indication 85828009
Infection by larvae of Trichinella spiralis indication 88264003
Pruritus ani indication 90446007
Acute lymphoid leukemia indication 91857003 DOID:9952
Subacute bursitis indication 109298000
Dermatitis herpetiformis indication 111196000 DOID:8505
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Mycosis fungoides indication 118618005
Uveitis indication 128473001 DOID:13141
Aspiration pneumonitis indication 155597006
Asthma indication 195967001 DOID:2841
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Transplanted organ rejection indication 213148006
Scalp psoriasis indication 238608008
Adrenogenital disorder indication 267395000 DOID:0050811
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Seasonal allergic rhinitis indication 367498001
Disorder of eye indication 371405004 DOID:5614
Adrenal cortical hypofunction indication 386584007 DOID:10493
Erythroderma indication 399992009
Primary cutaneous T-cell lymphoma indication 400122007
Asthma management indication 406162001
Autoimmune hemolytic anemia indication 413603009 DOID:718
Giant cell arteritis indication 414341000 DOID:13375
Synovitis indication 416209007 DOID:2703
Aphthous ulcer of mouth indication 426965005 DOID:9663
Post traumatic osteoarthritis indication 699262001
Severe Ocular Inflammation indication
Chronic Non-Allergic Rhinitis indication
Cystic Aponeurosis Tumor indication
Systemic Dermatomyositis indication
Allergic Rhinitis Prevention indication
Gingival Disorders indication
Erythroblastic Anemia indication
Transfusion Reaction Urticaria indication
Vitrectomy Adjunct to Enhance Visualization indication
Synovitis due to Osteoarthritis indication
Respiratory distress syndrome in the newborn off-label use 46775006
Congenital hypoplastic anemia off-label use 88854002 DOID:1339
Severe chronic obstructive pulmonary disease off-label use 313299006
Neonatal Bronchopulmonary Dysplasia off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Fungal infection of eye contraindication 31194008
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Herpes zoster keratoconjunctivitis contraindication 42448002
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Tuberculosis of eye contraindication 49107007
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Candidiasis of mouth contraindication 79740000 DOID:14262
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Oral infection contraindication 275393007
Varicella-zoster virus infection contraindication 309465005
Viral eye infection contraindication 312132001
Osteopenia contraindication 312894000
Skin irritation contraindication 367466007
Herpes zoster keratitis contraindication 397573005
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Atrophoderma contraindication 399979006
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Nasal Septal Ulcers contraindication
Ornithine Carbamyltransferase Deficiency contraindication
Periodontal Infections contraindication
Nasal Candidiasis contraindication
Nasal Trauma contraindication
Oropharyngeal Candidiasis contraindication
Uncontrolled Bacterial Infections contraindication
Untreated Fungal Infection contraindication
Arginosuccinate Lyase Deficiency contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.08 acidic
pKa2 11.78 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST EC50 9.30 WOMBAT-PK CHEMBL
Annexin A1 Cytosolic other WOMBAT-PK
Progesterone receptor Transcription factor Ki 7.64 DRUG MATRIX

External reference:

IDSource
D00983 KEGG_DRUG
4017597 VANDF
C2608734 UMLSCUI
CHEBI:71418 CHEBI
1TA PDB_CHEM_ID
CHEMBL1504 ChEMBL_ID
6436 PUBCHEM_CID
D014222 MESH_DESCRIPTOR_UI
F446C597KA UNII
2867 IUPHAR_LIGAND_ID
DB00620 DRUGBANK_ID
10761 RXNORM
2967 MMSL
5614 MMSL
6440 MMSL
002189 NDDF
395913005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KENULLLOG-40 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0293 INJECTION, SUSPENSION 40 mg INTRAMUSCULAR NDA 21 sections
KENULLLOG-80 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0315 INJECTION, SUSPENSION 80 mg INTRAMUSCULAR NDA 21 sections
KENULLLOG-10 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0494 INJECTION, SUSPENSION 10 mg INTRA-ARTICULAR NDA 22 sections
TRIESENCE HUMAN PRESCRIPTION DRUG LABEL 1 0065-0543 INJECTION, SUSPENSION 40 mg OPHTHALMIC NDA 23 sections
Good Sense Nasal Allergy HUMAN OTC DRUG LABEL 1 0113-0443 SPRAY, METERED 55 ug NULLSAL ANDA 16 sections
basic care nasal allergy HUMAN OTC DRUG LABEL 1 0113-7005 SPRAY, METERED 55 ug NULLSAL ANDA 15 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0002 CREAM 5 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0003 CREAM 0.25 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0004 CREAM 1 mg TOPICAL ANDA 17 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0005 OINTMENT 0.25 mg TOPICAL ANDA 19 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0006 OINTMENT 1 mg TOPICAL ANDA 19 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0168-0081 CREAM 1 mg TOPICAL ANDA 16 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0168-0089 OINTMENT 1 mg TOPICAL ANDA 19 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0336 LOTION 0.25 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0337 LOTION 1 mg TOPICAL ANDA 17 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0165 CREAM 0.25 mg TOPICAL ANDA 18 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0170 CREAM 1 mg TOPICAL ANDA 18 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0175 CREAM 5 mg TOPICAL ANDA 18 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0316-0223 CREAM 1 mg TOPICAL ANDA 18 sections
Allergy Nasal HUMAN OTC DRUG LABEL 1 0363-0811 SPRAY, METERED 55 ug NULLSAL ANDA 16 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0251 CREAM 1 mg TOPICAL ANDA 18 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0317 CREAM 0.25 mg TOPICAL ANDA 17 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0318 CREAM 5 mg TOPICAL ANDA 17 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0150 CREAM 1 mg TOPICAL ANDA 11 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0155 OINTMENT 1 mg TOPICAL ANDA 11 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0703-0241 INJECTION, SUSPENSION 40 mg INTRA-ARTICULAR ANDA 20 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0703-0243 INJECTION, SUSPENSION 40 mg INTRA-ARTICULAR ANDA 20 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0703-0245 INJECTION, SUSPENSION 40 mg INTRA-ARTICULAR ANDA 20 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0713-0225 CREAM 1 mg TOPICAL ANDA 18 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0713-0226 CREAM 0.25 mg TOPICAL ANDA 18 sections